FDA-cleared profile

Fibresolve (with PCCP)

Imvaria, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.

Clinical role
Adjunct lung-CT classification and referral support before invasive testing.
Images and patients
CT/CTA · Lungs and interstitial lung disease patterns
Key limitation
Keep in mind: The FDA labeling states that Fibresolve is adjunctive, must be used with history, symptoms, other tests, and professional judgment, and is not a replacement for multidisciplinary or invasive evaluation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Lungs and interstitial lung disease patterns Input: DICOM-compliant lung CT studies from patients aged over 22 years with pulmonary symptoms.
  • Who uses it?Intended users: Clinicians qualified in care of lung disease, including clinicians caring for patients with interstitial lung disease.
  • What does the software produce?Output: A report containing patient and technical information and a binary result suggesting the classified disease pattern.
  • What is its most important limitation?Key limitation: The FDA labeling states that Fibresolve is adjunctive, must be used with history, symptoms, other tests, and professional judgment, and is not a replacement for multidisciplinary or invasive evaluation.

Clinical takeaway. Clinical role: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports only non-clinical testing: software verification and validation per IEC 62304, whose results indicate the subject device is equivalent to the predicate. It also describes a predetermined change control plan under which future model modifications are evaluated via pre-specified statistical analyses to ensure, at minimum, non-inferior absolute performance. No clinical performance results are reported in the document. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Adjunct lung-CT classification and referral support before invasive testing.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM-compliant lung CT studies from patients aged over 22 years with pulmonary symptoms.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
A report containing patient and technical information and a binary result suggesting the classified disease pattern.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Interstitial-lung-disease referral and multidisciplinary discussion workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Clinicians qualified in care of lung disease, including clinicians caring for patients with interstitial lung disease.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling states that Fibresolve is adjunctive, must be used with history, symptoms, other tests, and professional judgment, and is not a replacement for multidisciplinary or invasive evaluation.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports only non-clinical testing: software verification and validation per IEC 62304, whose results indicate the subject device is equivalent to the predicate. It also describes a predetermined change control plan under which future model modifications are evaluated via pre-specified statistical analyses to ensure, at minimum, non-inferior absolute performance. No clinical performance results are reported in the document. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "SUMMARY OF NON-CLINICAL TESTING Software Verification and Validation (per IEC 62304) were performed to demonstrate safety based on current industry standards. The results of these tests indicate that the subject device is equivalent to the predicate device." … "Fibresolve includes a predetermined change control plan (PCCP), detailing the specific modifications (SaMD Pre-Specifications (SPS)) that may be made to the device". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports only non-clinical testing: software verification and validation per IEC 62304, whose results indicate the subject device is equivalent to the predicate. It also describes a predetermined change control plan under which future model modifications are evaluated via pre-specified statistical analyses to ensure, at minimum, non-inferior absolute performance. No clinical performance results are reported in the document. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "SUMMARY OF NON-CLINICAL TESTING Software Verification and Validation (per IEC 62304) were performed to demonstrate safety based on current industry standards. The results of these tests indicate that the subject device is equivalent to the predicate device." … "Fibresolve includes a predetermined change control plan (PCCP), detailing the specific modifications (SaMD Pre-Specifications (SPS)) that may be made to the device". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252041 FDA evidence package for Fibresolve (with PCCP)

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationLungs and interstitial lung disease patterns
  • Scopeexact submission
  • Tested versionFibresolve with PCCP
  • IndependenceSponsor or vendor study

K252041

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K252041 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant lung CT studies from patients aged over 22 years with pulmonary symptoms.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K252041: Fibresolve (with PCCP)

  2. Routing

    Source context, not route validation: The FDA package describes lung CT DICOM input, a cloud image receiver API, image ingestion and analysis, and output through an API to a hospital or clinic workflow.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K252041: Fibresolve (with PCCP)

  3. AI processing

    Source context, not route validation: The FDA package describes cloud software and API integration or manual manufacturer submission; current hosting, security, availability, retention, and contractual boundaries remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K252041: Fibresolve (with PCCP)

  4. Returned objects

    Source context, not route validation: A report containing patient and technical information and a binary result suggesting the classified disease pattern.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K252041: Fibresolve (with PCCP)

  5. Viewer/worklist/report

    Unresolved route: A report containing patient and technical information and a binary result suggesting the classified disease pattern.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K252041: Fibresolve (with PCCP)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes cloud software and API integration or manual manufacturer submission; current hosting, security, availability, retention, and contractual boundaries remain unknown.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes lung CT DICOM input, a cloud image receiver API, image ingestion and analysis, and output through an API to a hospital or clinic workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by clinicians qualified in care of lung disease, including clinicians caring for patients with interstitial lung disease. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K252041.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K252041.

exact submission · checked 2026-09-04

Deployment boundary

The FDA package describes cloud software and API integration or manual manufacturer submission; current hosting, security, availability, retention, and contractual boundaries remain unknown.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes lung CT DICOM input, a cloud image receiver API, image ingestion and analysis, and output through an API to a hospital or clinic workflow.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K252041.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252041
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Lungs and interstitial lung disease patterns
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-11-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
8Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. The records name Fibresolve but do not identify the K252041 with-PCCP configuration or tested build; PMID 42587682 identifies an FDA-authorized product through the earlier DEN220040 record rather than K252041. The current discovery snapshot contains 8 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K252041: Fibresolve (with PCCP)

    U.S. Food and Drug Administration - Published 2025-11-07 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Fibresolve (with PCCP) model card (K252041)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K252041 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253560

Enhanced Boundary for PCCT

Ge Medical Systems, LLC

Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.

Modality
CT/CTA
Anatomy
Head
Decision
2026-06-24
FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and derived outputs remain submission-specific.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

Authorized purpose: SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
FDA-cleared K250290

SurgiTwin

Twinsight

Authorized purpose: SurgiTwin is a web pre-surgical knee-planning system that uses patient CT images to provide two-dimensional and three-dimensional planning information and a PDF report for adults older than 22.

Modality
CT/CTA
Anatomy
Knee
Decision
2025-08-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history